Click a Partner’s link below to immediately visit the area of your choice.
PAAB
Montreal InVivo
IMS Health
BioAlberta
Toronto Biotechnology Initiative
Ottawa Centre for Research and Innovation
News from PAAB
Learn the regulations and guidelines that embody the pharmaceutical industry’s commitment to the highest standard of professional conduct. Pharmahorizons is the authorized training partners of the PAAB and Rx&D.
Don’t miss this important seminar:
PAAB Code: Strategies, Tools and Techniques to Speed Approval of Your Submission
Toronto: November 21, 2007
Montreal: November 14, 2007
Download the course brochure
News from Montreal InVivo
Montreal is Canada’s largest life science cluster. Each month, Pharmahorizons will showcase news, trends and events in the greater Montreal area.
Canada-based ethica Clinical Research Inc. establishes joint venture with India-based Matrix Group
Montreal – ethica Clinical Research Inc. (“ethica”), a Contract Research Organization (CRO) headquartered in Montreal has formed a joint venture with the Hyderabad-based Matrix Group. The new company, ethicamatrix CRO Pvt Ltd (“ethicamatrix”), will manage contract research services in India on behalf of North American and European pharmaceutical and biotechnology companies, as well as on behalf of domestic Indian life sciences companies. The initial activities of ethicamatrix will focus on clinical research services including study monitoring, data management, and investigator training.
ethica is the first Canadian CRO to establish a joint venture with a similar Indian firm. Established in 1996 in Hyderabad, Matrix Group is active in the life sciences, aqua technology, and agricultural sectors. ethica is the sole Canadian-owned CRO to position itself in India.
As the first and only CRO in the world to earn full accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP), ethica is uniquely certified to bring the highest of global standards to contract research in India.
Read the full report.
Neptune Technologies begins trading on NASDAQ
Laval, Québec, CANADA– Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced that its shares began trading on the NASDAQ Stock Market under the symbol NEPT on Monday, August 13 at the opening bell. Neptune Technologies & Bioressources (NTB) extracts, scientifically validates, and markets scientifically validated health ingredients extracted from marine biomasses; the Company currently provides the world’s only FDA-allowed oil from krill.
Read the full report.
Advitech announces positive pre-clinical results for wound-healing application
QUEBEC CITY, Oct. 10 /CNW Telbec/ - Advitech Inc. (”Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) today announced that two milk-derived protein extracts from its XP-828L technological platform have demonstrated wound-healing properties in an in vivo study conducted by Dr. Charles Doillon of the Oncology and Molecular Endocrinology Research Centre at the Centre Hospitalier de l’Université Laval (CHUL). Dr. Doillon is a recognized researcher in the field of wound healing and angiogenesis. The study has demonstrated that both protein extracts could significantly impact the wound-healing response, especially the formation of regenerated collagen fibre and its remodelling in wound tissue.
Read the full report.
Montreal InVivo and Pharmahorizons are Partners
- Back to top -
Pharmahorizons is pleased to welcome our latest Partner, IMS, with their wide range of seminars.
News from IMS Health
Learning Solutions and Change Management Seminars.
IMS courses make use of the latest learning tools combining conceptual content, sophisticated computer-based simulation work, and exercises with real data to ensure maximum impact and retention.
Click here to download the IMS Health brochures with 10 new courses
All Roads Lead to China
While growth in the global pharmaceutical market remains anemic, rising just six to seven percent in 2006, emerging economies are galloping ahead to outpace growth in mature markets like the United States and major European nations. Pharmaceutical companies are finding bright spots outside of these traditional markets to compensate for increasingly flat global growth. Within the last five years, the emerging markets’ share of growth in the global pharmaceutical market has grown from 5 percent to 31 percent. The most stellar opportunity lies in China, which continues to emerge as a significant healthcare market. To look at growth in China is to see that all roads lead to this awakening giant that will dominate as the world’s largest economy by 2040. IMS Global Consulting’s Raymond Hill, Stephen Walter and Mandy Chui explore these dynamics.
Read the full report.
IMS Health Announces 12 Percent Revenue Growth
NORWALK, CT, October 17, 2007 – IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced third-quarter 2007 revenue of $538.8 million, up 12 percent or 8 percent on a constant-dollar basis, compared with revenue of $482.7 million for the third quarter of 2006.
Read the full report.
IMS and Pharmahorizons are Partners
- Back to top -
News from Toronto’s BioPharma Community
Canadian Researchers find drug-coated stents help to reduce the need for repeat cardiac surgeries …
Canadian Researchers find drug-coated stents help to reduce the need for repeat cardiac surgeries and don’t significantly increase the rate of death or risk of heart attack. That’s the conclusion of a new study published in the New England Journal of Medicine that seeks to clear up the confusion about the safety of the expensive devices. This latest study, conducted at ICES in collaboration with researchers from Sunnybrook Health Sciences Centre and the University of Toronto, looked at more than 7,500 patients, half of whom received drug-eluting stents while the other half received conventional bare metal stents, between December 2003 and March 2005.
Source: Life Sciences News Briefs: Industry Canada
Louise Leduc Tel: (613) 954-4715
E-mail: leduc.louise@ic.gc.ca
Read the full report.
Ontario’s wait time system wins innovation award
Ottawa— “September’s signing ceremony with federal Finance Minister Flaherty amending the Canada-US Tax Treaty to recognize limited liability corporations is a tremendous accomplishment for the investment climate in Canada and our international colleagues will take notice,” said Peter Brenders, President & CEO, BIOTECanada
Read the full report.
Canada’s biotechnology industry lauds the government’s action improving Canada’s investment climate
TORONTO – Cancer Care Ontario has received a prestigious gold award for Innovation Management from the Institute of Public Administration of Canada (IPAC) for developing and deploying a Wait Time Information System (WTIS), a critical component of Ontario’s Wait Time Strategy.
Read the full report.
The Toronto Biotechnology Initiative is the voice of the life sciences in the Greater Toronto Area. TBI and Pharmahorizons are Partners.
- Back to top -
News from the OCRI Life Sciences
Web portal helps Canadians care for loved ones
OTTAWA – Canadians who care for family and friends will soon have access to an innovative web portal tool that will equip them with information they need to provide the care their loved ones deserve.
The bilingual (French and English) web portal tool will contain information on providing care, respite supports, financial advice, discussion boards for connecting with one another and a Caregiver Electronic Record (CER), which will serve to connect caregivers to home and community care sectors.
Read the full report.
John Baird and the Ottawa Gala give $35,000 to OCRI School Breakfast Program
OTTAWA– John Baird, Member of Parliament for Ottawa-West Nepean presented a cheque for $35,000 as Honourary Chair of the Ottawa Gala to the Ottawa Centre for Research and Innovation (OCRI) School Breakfast Program on October 2nd. The funds were part of the proceeds from the must-attend event of the Ottawa social season.
Mr. Baird, alongside representatives from Fund for a New Generation, spent the morning serving breakfast to some eager kids at the Grant Alternative School in West Ottawa. The breakfast program offers a healthy start to the day for 8,500 Ottawa children each year.
Read the full report.
Driving Global Innovation & Commercialization through Partnerships
BioNorth 2007, Canada’s International Biotechnology and Life Sciences Conference will be held at the Ottawa Congress Centre on November 19 and 20th, 2007 in Ottawa, Ontario (CANADA). This year’s theme is Driving Global Innovation & Commercialization through Partnerships.
The BioNorth Biotechnology and Life Sciences Conference, now in its 14th year, has grown from a small regional conference to being a showcase of Ontario and International business strengths in the Innovation and Commercialization of life science technologies. This international event attracts delegates and speakers from across the country and around the world. OCRI Life Sciences is proud to provide a forum for the Biotechnology and Life Sciences community to discover, learn, network and partner in a truly unique location – Canada’s capital.
BioNorth provides an opportunity for International communities to focus on bringing select companies or specific targeted business opportunities while at the same time providing a venue for Ontario’s companies and communities within the life science and biotechnology sectors to showcase their strengths (including Cleantech – bioproducts, energy and environmental).
For more information on the conference contact: info@bionorth.ca.
2007 Ottawa Report – Ottawa Growing its Innovation Economy
OTTAWA– OCRI, Ottawa’s lead economic development agency, released the 2007 Ottawa Report, formally known as the OCRI Report in September. This annual initiative provides a comprehensive and authoritative perspective on the most recent economic, technology and educational indicators for Ottawa. The Report compiles statistical data which shows the city’s strengths and points out areas needing improvement to maintain economic growth.
Read the full report.
The Ottawa Centre for Research and Innovation (OCRI) is the voice of the life sciences in the greater Ottawa area. OCRI and Pharmahorizons are Partners.
- Back to top -
News from BioAlberta
BioAlberta is the central voice and the organizing hub for the bio-industry in Alberta.
Edmonton—The Alberta Heritage Foundation for Medical Research (AHFMR)’s ForeFront
Edmonton—The Alberta Heritage Foundation for Medical Research (AHFMR)’s ForeFront program and BioAlberta are joining forces to give early stage Alberta biotechnology companies an opportunity to make global business connections.
Operating income in the third quarter of 2007 was $117.1 million, up 1 percent on both a reported and constant-dollar basis, compared with $115.4 million in the year-earlier period.
Read the full report.
Cyplasin-SC TM Kills Melanoma Cells, Even Derived From Different Patients but Leaves Normal Human Cells Unharmed
Edmonton—It is well known that many cancer types – or even the same cancer in different patients – show different sensitivities to a given therapeutic treatment. In earlier studies Cyplasin-SCTM has shown to be an efficient killer of many cancer cell types whereas normal human cells were left intact. An independent third party study conducted by Professor di Liegro, Department of Medicine of the University of Palermo, Italy, tested Cyplasin-SCTM on 5 melanoma cell lines derived from 5 different patients to determine if all melanoma cells were equally susceptible to Cyplasin-SCTM or if there were specific melanomas that did not respond to the drug. As a control to these experiments normal human cells were also exposed to the same concentrations of Cyplasin-SCTM used for the melanoma experiments.
Read the full report.
Alberta’s Green Technology to Help Meet China’s Power Needs
Alberta’s success in producing bioenergy from agricultural waste could soon turn an operational cost and environmental problem for Chinese farmers into a source of self-sufficient electricity and new revenue. The IMUS™ biogas system, originally developed by the Alberta Research Council, Highmark Renewables and its partners, is being adapted for small-scale use in the Chinese market with help from the Alberta government.
Construction and testing of the Chinese demonstration plant will take about two years and start this fall. Upon completion, the plant will annually process about 3,000 tonnes of dairy manure as the main feedstock and generate excess electricity equivalent to the needs of about 150 Alberta homes. Based on this plant’s success, future IMUS™ plants may be built in China, creating a business opportunity for Alberta industry and laying the groundwork to adapt the technology for the average Alberta farmer.
Source: Alberta Research Council
$40 million National Institute Nanotechnology Innovation Centre is open for business
The National Institute for Nanotechnology Innovation Centre located on the University of Alberta campus in Edmonton, Alberta, opened its doors in October. The 15,000 square metre, $40 million institute is one of the world’s most technologically advanced research facilities with the latest generation of scientific equipment, including electron and scanning probe microscopes and chemical and material analysis instruments.
Read the full report.
BioAlberta and Pharmahorizons are Partners
- Back to top -